Biologics products took center stage last week, on both the approval and submission sides – until Jazz Pharmaceuticals PLC and PharmaMar SA’s novel alkylating drug Zepzelca nabbed US FDA approval two months before its user fee goal date.
Pfizer Inc.’s Nyvebria and Mylan NV and Biocon Ltd.’s Semglee took different regulatory paths to approval. Nyvebria,...





